Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilapladib + itraconazole
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Rilapladib + itraconazole** is a combination of two small molecules: rilapladib, a potent and selective inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2), and itraconazole, a triazole antifungal agent that inhibits fungal cytochrome P450 enzyme lanosterol 14α-demethylase, thereby impairing ergosterol synthesis. This combination has been studied primarily to assess pharmacokinetic interactions between rilapladib and itraconazole[1]. Rilapladib was developed for atherosclerosis and investigated for Alzheimer's disease, while itraconazole is approved for various systemic fungal infections. The combination is not an approved therapy; clinical trials have evaluated their co-administration to measure the effect of itraconazole (a strong CYP3A4 inhibitor) on rilapladib metabolism[1].
- Other names
- rilapladib + itraconazole
02
Targets
PLA2G7 (Platelet-activating factor acetylhydrolase)CYP3A4 (Cytochrome P450 3A4)CYP51A1 (Sterol 14α-demethylase)
Beyond the preview
Go deeper on rilapladib + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilapladib + itraconazole.